Yıl: 2023 Cilt: 63 Sayı: 2 Sayfa Aralığı: 126 - 131 Metin Dili: İngilizce DOI: 10.14744/hnhj.2021.59265 İndeks Tarihi: 30-05-2023

The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors

Öz:
Introduction: Overexpression and the amplification of proto-oncogenic c-erythroblastic oncogene B (c-erbB-2) (HER-2/neu) encode transmembrane growth factor glycoprotein and are a part of the type I receptor tyrosine-protein kinase. It is known to play a role in the treatment of breast and stomach carcinomas. C-erbB-2 overexpression and amplification in urothelial carcinomas have also been demonstrated in many studies. However, possible treatment options and prognostic values are still not sufficiently defined. This study aims to determine the overexpression rate of c-erbB-2 in urothelial carcinomas. In ad dition, we sought to determine if there was a relationship between c-erbB-2 overexpression and clinical-pathological prog nostic factors, such as histological grade, pathological stage, lymph node and distant organ metastasis, and survival time. Methods: C-erbB2 overexpression was examined using an immunohistochemical method performed on paraffin block samples of patients diagnosed with primary bladder urothelial carcinoma (n=41). The relationship of the data obtained after this examination with classical clinical-pathological prognostic factors, such as histological grade, pathological stage, regional lymph node metastasis, distant organ metastasis, and survival, was investigated. The obtained data were evaluated statistically. The alpha significance value was 0.05. Results: C-erbB-2 overexpression was positive in 9.75% (4/41) of the cases. c-erbB-2-positive tumors were all found to be at a high level. One patient was in stage T2, one stage T3, and two in stage T4. Three positive cases had lymph node metastasis; one patient did not have lymph node metastasis. Remote organ metastasis was not observed in any positive cases, and all positive cases were reported to survive. The fact that 75% (3/4) of the positive cases were lymph node metastasis may contribute to the literature. Discussion and Conclusion: Standardized laboratory methods should be used and studied in large series, including more patients representing various races to evaluate c-erbB-2 overexpression and amplification status in urothelial tumors as a treatment option with prognostic value.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Li W, Wang Y, Tan S, Rao Q, Zhu T, Huang G, et al. Overexpres sion of Epidermal Growth Factor Receptor (EGFR) and HER-2 in bladder carcinoma and its association with patients' clinical features. Med Sci Monit 2018;24:7178–85.
  • 2. Sánchez-Carbayo M, Cordon-Cardó C. Molecular alterations associated with bladder cancer progression. Semin Oncol 2007;34:75–84.
  • 3. Tsai YS, Cheng HL, Tzai TS, Chow NH. Clinical significance of ErbB receptor family in urothelial carcinoma of the blad der: A systematic review and meta-analysis. Adv Urol 2012;2012:181964.
  • 4. El Gehani K, Al-Kikhia L, Emaetig F, Syrjänen K, Al-Fituri O, Elza gheid A. Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder. Libyan J Med 2012;7.
  • 5. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, et al. Distinctive expression pattern of ErbB family recep tors signifies an aggressive variant of bladder cancer. J Urol 2008;179:353–8.
  • 6. Tapia C, Glatz K, Novotny H, Lugli A, Horcic M, Seemayer CA, et al. Close association between HER-2 amplification and over expression in human tumors of non-breast origin. Mod Pathol 2007;20:192–8.
  • 7. Tschui J, Vassella E, Bandi N, Baumgartner U, Genitsch V, Rotzer D, et al. Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Arch 2015;466:703–10.
  • 8. Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Med 2015;4:844–52.
  • 9. Cox G, Vyberg M, Melgaard B, Askaa J, Oster A, O'Byrne KJ. Her ceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int J Cancer 2001;92:480–3.
  • 10. Zhau HE, Zhang X, von Eschenbach AC, Scorsone K, Babaian RJ, Ro JY, et al. Amplification and expression of the c-erb B-2/ neu proto-oncogene in human bladder cancer. Mol Carcinog 1990;3:254–7.
  • 11. Gandour-Edwards R, Lara PN Jr, Folkins AK, LaSalle JM, Beck ett L, Li Y, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002;95:1009–15.
  • 12. Wülfing C, von Struensee D, Bierer S, Bögemann M, Hertle L, Eltze E. Expression of Her2/neu in locally advanced bladder cancer: Implication for a molecular targeted therapy. Aktuelle Urol [Article in German] 2005;36:423–9.
  • 13. Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, Tobiume M, et al. Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder can cer. Oncol Rep 2007;18:3–7.
  • 14. Moustakas G, Kampantais S, Nikolaidou A, Vakalopoulos I, Tzioufa V, Dimitriadis G. HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle invasive bladder cancer on intravesical therapy. J Int Med Res 2020;48:300060519895847.
  • 15. Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieille fond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients. Ann Oncol 2010;21:815–9.
  • 16. El Ochi MR, Oukabli M, Bouaiti E, Chahdi H, Boudhas A, Al laoui M, et al. Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. BMC Clin Pathol 2017;17:3.
  • 17. Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P, Sakr WA, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7:2440–7.
  • 18. Al-Ahmadie H, Iyer G. Updates on the genetics and molecu lar subtypes of urothelial carcinoma and select variants. Surg Pathol Clin 2018;11:713–23.
  • 19. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315–22.
  • 20. Yorozu T, Sato S, Kimura T, Iwatani K, Onuma H, Yanagisawa T, et al. HER2 status in molecular subtypes of urothelial car cinoma of the renal pelvis and ureter. Clin Genitourin Cancer 2020;18:e443–9.
  • 21. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaisham payan U, Lara PN Jr, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth fac tor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin On col 2007;25:2218–24.
  • 22. Matsubara H, Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, et al. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: Comparative study of immuno histochemistry and fluorescent in situ hybridization. Oncol Rep 2008;19:57–63.
APA GÖNÜLTAŞ A, KILIÇ G, aker f, Aliustaoglu M (2023). The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors. , 126 - 131. 10.14744/hnhj.2021.59265
Chicago GÖNÜLTAŞ AYLİN,KILIÇ GÜRAY,aker fügen,Aliustaoglu Mehmet The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors. (2023): 126 - 131. 10.14744/hnhj.2021.59265
MLA GÖNÜLTAŞ AYLİN,KILIÇ GÜRAY,aker fügen,Aliustaoglu Mehmet The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors. , 2023, ss.126 - 131. 10.14744/hnhj.2021.59265
AMA GÖNÜLTAŞ A,KILIÇ G,aker f,Aliustaoglu M The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors. . 2023; 126 - 131. 10.14744/hnhj.2021.59265
Vancouver GÖNÜLTAŞ A,KILIÇ G,aker f,Aliustaoglu M The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors. . 2023; 126 - 131. 10.14744/hnhj.2021.59265
IEEE GÖNÜLTAŞ A,KILIÇ G,aker f,Aliustaoglu M "The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors." , ss.126 - 131, 2023. 10.14744/hnhj.2021.59265
ISNAD GÖNÜLTAŞ, AYLİN vd. "The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors". (2023), 126-131. https://doi.org/10.14744/hnhj.2021.59265
APA GÖNÜLTAŞ A, KILIÇ G, aker f, Aliustaoglu M (2023). The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors. Haydarpaşa Numune Medical Journal, 63(2), 126 - 131. 10.14744/hnhj.2021.59265
Chicago GÖNÜLTAŞ AYLİN,KILIÇ GÜRAY,aker fügen,Aliustaoglu Mehmet The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors. Haydarpaşa Numune Medical Journal 63, no.2 (2023): 126 - 131. 10.14744/hnhj.2021.59265
MLA GÖNÜLTAŞ AYLİN,KILIÇ GÜRAY,aker fügen,Aliustaoglu Mehmet The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors. Haydarpaşa Numune Medical Journal, vol.63, no.2, 2023, ss.126 - 131. 10.14744/hnhj.2021.59265
AMA GÖNÜLTAŞ A,KILIÇ G,aker f,Aliustaoglu M The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors. Haydarpaşa Numune Medical Journal. 2023; 63(2): 126 - 131. 10.14744/hnhj.2021.59265
Vancouver GÖNÜLTAŞ A,KILIÇ G,aker f,Aliustaoglu M The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors. Haydarpaşa Numune Medical Journal. 2023; 63(2): 126 - 131. 10.14744/hnhj.2021.59265
IEEE GÖNÜLTAŞ A,KILIÇ G,aker f,Aliustaoglu M "The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors." Haydarpaşa Numune Medical Journal, 63, ss.126 - 131, 2023. 10.14744/hnhj.2021.59265
ISNAD GÖNÜLTAŞ, AYLİN vd. "The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors". Haydarpaşa Numune Medical Journal 63/2 (2023), 126-131. https://doi.org/10.14744/hnhj.2021.59265